Publications

Journals

• Jesudason DR; Monteiro MP; McGowan BM; Neary NM; Park AJ; Philippou E; Small CJ; Frost GS; et alGhatei MA; Bloom SR. (Mar 2007). Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr. 97:426-429. DOI.
• Park A; Edwards M; Donaldson M; Ghatei M; Meeran K. (1 Dec 2003). A case of false immunoassay results due to assay interference. ENDOCRINE-RELATED CANCER. 10:507-507. Author weblink.
• Park A; Bloom SR. (15 Jun 2004). Peptides and obesity: the PYY3-36 story. REGULATORY PEPTIDES. 119:1-2. Author weblink DOI.
• Park A; Le Roux C; Frost P; Bloom S. (16 Sep 2000). Chemical pathology. BMJ. 321:S2-S7262.
• Park A; Edwards M; Donaldson M; Ghatei M; Meeran K. (8 Mar 2003). Lesson of the week: interfering antibodies affecting immunoassays in woman with pet rabbits. BMJ. 326:541-542. DOI.
• Cohen MA; Ellis SM; Le Roux CW; Batterham RL; Park A; Patterson M; Frost GS; Ghatei MA; et alBloom SR. (Oct 2003). Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 88:4696-4701.
• Wynne K; Park AJ; Small CJ; Meeran K; Ghatei MA; Frost GS; Bloom SR. (Dec 2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 30:1729-1736. DOI.
• Druce MR; Wren AM; Park AJ; Milton JE; Patterson M; Frost G; Ghatei MA; Small C; et alBloom SR. (Sep 2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond). 29:1130-1136. DOI.
• Wynne K; Park AJ; Small CJ; Patterson M; Ellis SM; Murphy KG; Wren AM; Frost GS; et alMeeran K; Ghatei MA; Bloom SR. (Aug 2005). Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 54:2390-2395.
• Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; et alWang F; Kent AS; Frost GS; Ghatei MA; Bloom SR. (Dec 2005). Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 146:5120-5127. DOI.
• Park AJ; Bloom SR. (Mar 2005). Neuroendocrine control of food intake. Curr Opin Gastroenterol. 21:228-233.
• Batterham RL; Le Roux CW; Cohen MA; Park AJ; Ellis SM; Patterson M; Frost GS; Ghatei MA; et alBloom SR. (Aug 2003). Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 88:3989-3992.
• Dakin CL; Small CJ; Park AJ; Seth A; Ghatei MA; Bloom SR. (Dec 2002). Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab. 283:E1173-E1177. DOI.

Conferences

• Park A; Sileno A; Brandt G; Quay S; Bloom S. Nasal peptide YY3-36: Phase 1 dose ranging and safety study in healthy subjects. 13th European Congress on Obesity, 26 May 2004 - 29 May 2004. 28:S222-S222. NATURE PUBLISHING GROUP (1 May 2004). Author weblink.